<DOC>
	<DOCNO>NCT02631460</DOCNO>
	<brief_summary>This study compare efficacy safety S1 plus carboplatin ( C ) follow S1 pemetrexed plus carboplatin ( C ) follow pemetrexed patient epidermal growth factor receptor ( EGFR ) wild type advance nonsquamous non-small-cell lung cancer ( NSCLC ) .Patients previously untreated EGFR wild type stage IIIB IV nonsquamous NSCLC Eastern Cooperative Oncology Group performance status 0 1 randomly assign receive pemetrexed 500 mg/m2 S1（80-120 mg/d）combined carboplatin area curve ( AUC ) 5 every 3 week four cycle . Eligible patient receive maintenance disease progression : pemetrexed S1 . The primary end point non-inferiority study progression free survival（PFS）</brief_summary>
	<brief_title>S1 vs.Pemetrexed Plus Carboplatin Patients With EGFR Wild Type Stage IIIB IV Nonsquamous NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Chemotherapynaive patient histologically cytologically confirm nonsquamous NSCLC , classify stage IIIB amenable curative treatment stage IV ; EGFR wild type . 2 . At least one unidimensionally measurable lesion accord Response Evaluation Criteria Solid Tumors 3 . Eastern Cooperative Oncology Group performance status 0 1 4 . 18 ＜age＜75 year 5 . Patients adequate bone marrow reserve organ function . 6 . Prior radiation therapy permit complete least 4 week study treatment patient fully recover acute effect 7 . Written inform consent obtain directly every patient 8 . Estimated life expectancy least 12 week . 9 . Patient compliance geographic proximity allow adequate follow . 10 . Male female patient reproductive potential must use approved contraceptive method , appropriate 3 month study . Women childbearing potential must negative serum pregnancy test within 7 day prior study enrollment . 1 . Brain metastasis associated central nervous symptom ( patient eligible symptom control steroid treatment ) ; 2 . Serious infection serious complication . 3 . Uncontrolled thirdspace fluid retention study entry . unable interrupt aspirin nonsteroidal antiinflammatory drug unable unwilling take folic acid , vitamin B12 , corticosteroids 4 . Have prior malignancy NSCLC , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . 5 . Pregnant breast feeding . 6 . A distinct history drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>